


Target: STELLA PHARMA CORPORATION

Outline: R&D, manufacturing and sales of medical products and medical devices

Authorized Investment: 3.5 billion yen (maximum)



- Targeting world-first regulatory approval and commercialization of BNCT, a new type of cancer treatments
- Driving innovative medical technology development by open innovation across manufacturing industries and domestic academia